Compare Roivant Sciences Ltd. Common Shares (ROIV) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roivant Sciences Ltd. Common Shares vs 10X Genomics Inc — how do they compare? Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $24.72B), while 10X Genomics Inc trades at $78.99 (market cap $10.07B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 2.5× 10X Genomics Inc's market cap, and Roivant Sciences Ltd. Common Shares is more actively traded (6,279,442 versus 5,657,286). Which is the better fit depends on your goals — on Pluang, investors hold Roivant Sciences Ltd. Common Shares for 0 Days and 10X Genomics Inc for 92 Days on average.
| ROIV | TXG | |
|---|---|---|
Market Cap | $24.72B | $10.07B |
Volume | 6,279,442 | 5,657,286 |
Sector | Health | Health |
52-Week High | $41.81 | $97.74 |
52-Week Low | $16.04 | $11.48 |
Typical Hold Time | 0 Days | 92 Days |
Enterprise Value | $20.99B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roivant Sciences Ltd. Common Shares
Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
